Trial Profile
A Phase 3, Multicenter, Randomized, Long Term Study Of The Safety Of Tanezumab In Patients With Osteoarthritis Of The Knee Or Hip.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 May 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Pfizer
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 07 Jul 2011 Planned end date changed from 1 Oct 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
- 13 Dec 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.